Pulseless arrest: Difference between revisions
No edit summary |
No edit summary |
||
| Line 23: | Line 23: | ||
#Severe Hypovolemia | #Severe Hypovolemia | ||
#Obstruction | #Obstruction | ||
#*[[Tension | #*[[Tension pneumothorax]] | ||
#*[[Cardiac | #*[[Pericardial effusion and tamponade|Cardiac tamponade]] | ||
#*Massive [[Pulmonary | #*Massive [[Pulmonary embolism]] | ||
#Pump Failure | #Pump Failure | ||
===[[ACLS (Treatable Conditions)|Treatable ACLS Conditions]] (H's and T's)=== | ===[[ACLS (Treatable Conditions)|Treatable ACLS Conditions]] (H's and T's)=== | ||
*Hypovolemia | *Hypovolemia | ||
*[[ | *[[Hypoxemia]] | ||
*Hydrogen ion (i.e. acidemia) | *Hydrogen ion (i.e. acidemia) | ||
*[[Hypokalemia|Hypo]]/[[hyperkalemia]] | *[[Hypokalemia|Hypo]]/[[hyperkalemia]] | ||
*[[Hypothermia]] | *[[Hypothermia]] | ||
*[[Tension Pneumothorax]] | *[[Tension Pneumothorax]] | ||
*[[Cardiac | *[[Pericardial effusion and tamponade|Cardiac tamponade]] | ||
*[[Toxicology ( | *[[Toxicology (main)|Toxins]] | ||
*[[ | *[[Pulmonary embolism|Thrombosis, pulmonary]] | ||
*[[ | *[[Acute coronary syndrome (main)|Thrombosis, coronary]] | ||
===PEA Evaluation by QRS=== | ===PEA Evaluation by QRS=== | ||
| Line 79: | Line 79: | ||
#Place a second set of defib pads in an alternative location on the chest | #Place a second set of defib pads in an alternative location on the chest | ||
#Continue CPR | #Continue CPR | ||
#Deliver 360J | #Deliver 200J (or 360J if monophasic) simultaneously from both defibrillators | ||
#Continue CPR | #Continue CPR | ||
#Give [[Esmolol]] bolus at 0.5mg/kg and start drip at 0.1mg/kg | #Give [[Esmolol]] bolus at 0.5mg/kg and start drip at 0.1mg/kg | ||
#Deliver 360J | #Deliver 200J (or 360J if monophasic) simultaneously from both defibrillators | ||
#Continue CPR | #Continue CPR | ||
| Line 102: | Line 102: | ||
*[[ACLS (Main)]] | *[[ACLS (Main)]] | ||
*[[Double simultaneous external defibrillation]] | *[[Double simultaneous external defibrillation]] | ||
*[[Brain | *[[Brain death]] | ||
*[[Post | *[[Post cardiac arrest]] | ||
*[[Pediatric | *[[Pediatric pulseless arrest]] | ||
==External Links== | ==External Links== | ||
Revision as of 05:47, 27 December 2016
Immediate
- Start CPR
- Give oxygen
- Attach monitor/defibrilator
- Rhythm shockable?
V-Fib and Pulseless V-Tach (Shockable)
- Shock as quickly as possible and resume CPR immediately after shocking
- Biphasic - 200J
- Monophasic - 360 J
- Give Epi 1mg if (shock + 2min of CPR) fails to convert the rhythm
- Give antiarrhythmic if (2nd shock + 2min of CPR) again fails
- 1st line: Amiodarone 300mg IVP with repeat dose of 150mg as indicated
- 2nd line: Lidocaine 1-1.5mg/kg then 0.5-0.75mg/kg q5-10min
- Polymorphic V-tach: Magnesium 2g IV, followed by maintenance infusion
Asystole and PEA (Non-Shockable)
- Epi 1mg q3-5min
- Three major mechanisms of PEA (3 & 3 Rule)
- Severe Hypovolemia
- Obstruction
- Pump Failure
Treatable ACLS Conditions (H's and T's)
- Hypovolemia
- Hypoxemia
- Hydrogen ion (i.e. acidemia)
- Hypo/hyperkalemia
- Hypothermia
- Tension Pneumothorax
- Cardiac tamponade
- Toxins
- Thrombosis, pulmonary
- Thrombosis, coronary
PEA Evaluation by QRS
Differential based on QRS being narrow or wide and aided by ultrasound
QRS Narrow
Mechanical RV Problem – Ultrasound should show hyperdynamic LV and potential cause
- Cardiac tamponade
- Tension pneumothorax
- Mechanical hyperinflation
- Pulmonary embolism
- Acute MI with myocardial rupture
QRS Widened
Metabolic LV Problem – Ultrasound should show hypokinetic LV
- Severe hyperkalemia
- Sodium-channel blocker toxicity (Ex. Tricyclic (TCA) toxicity)
- Agonal rhythm
- Acute MI with pump failure
General
- A (adjunct) - Place oropharyngeal airway
- B (breathing) - place on Ventilator to assure slow ventilation rate (attach to BVM mask)
- 10-12 bpm, 500cc tidal volume, Fio2 100%
- C (compressions) - Switch out providers q pulse check; use metronome
- D - defibrillation
- May be ok to shock during compressions if wearing gloves and using biphasic device[1]
- A (advanced airway)
- Use LMA (NOT ET tube - no break in compressions required)
- B (advanced breathing)
- Connect LMA to Ventilator
- Pressure control 20, RR 10, insp rate 1.5-2s
- Connect LMA to Ventilator
- C (advanced circulation)
- Place IO instead of central line
- D (differential)
Refractory Ventricular Fibrillation
A patient is considered refractory after ≥3 defib, ≥3mg epi, and 300mg amio
DSED[2] & Esmolol for Failure of Standard ACLS[3]
- Place a second set of defib pads in an alternative location on the chest
- Continue CPR
- Deliver 200J (or 360J if monophasic) simultaneously from both defibrillators
- Continue CPR
- Give Esmolol bolus at 0.5mg/kg and start drip at 0.1mg/kg
- Deliver 200J (or 360J if monophasic) simultaneously from both defibrillators
- Continue CPR
Fibrinolytics
Dosing
- Alteplase 0.6mg/kg IV push x1 given over 15 min (± heparin 5000 unit bolus), and then repeated 30 min after if still no ROSC[4]
- Heparin may be bolused with tPA or after ROSC obtained
- Max doses of 50mg may be as efficacious as 100mg
- Consider at least 20min of CPR after last dose of tPA before ending code
Guidelines and Recommendations
- ACLS 2010 does not yet recommend routine thrombolytics (Class III)
- CHEST 2012 and ACLS 2010 recommends in acute PE or high suspicion[5]
- Class IIc and Class IIa, respectively
- 2 hr infusion time recommended over long, 24hr (CHEST Class IIc)
See Also
- ACLS (Main)
- Double simultaneous external defibrillation
- Brain death
- Post cardiac arrest
- Pediatric pulseless arrest
External Links
References
- ↑ Lloyd MS, Heeke B, Walter PF, and Langberg JJ. Hands-on defibrillation: an analysis of current flow through rescuers in direct contact with patients during biphasic external defibrillation. Circulation. 2008; 117:2510-2514.
- ↑ Hoch DH et al. Double Sequential External Shocks for Refractory Ventricular fibrillation. JACC 1994; 23: 1141 – 5.
- ↑ Driver BE, Debaty G, Plummer DW, et al. Use of esmolol after failure of standard cardiopulmonary resuscitation to treat patients with ventricular fibrillation. Resuscitation. 2014; 85(10):1337-1341.
- ↑ Böttiger BW et al. Lancet 2001;357:1583-5.
- ↑ Kearon C et al. Chest 2012; 141 (2)(suppl):e419s-e494s. Vanden Hoek TL et al. Circulation 2010; 122 (suppl):S829-S861.
